Follow-up Data Show ZYTIGA? Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy(Feb 12, 2013)

Orlando, Fla., February 12, 2013 ? Janssen Research & Development, LLC [Janssen] announced today that updated results showing ZYTIGA? (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer.....
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news